Puma Biotechnology
PBYI | NASDAQ
$7.34
-$0.43 (-5.53%)
At close: Nov 16, 2026, 4:00 PM ET
$7.20
-$0.14 (-1.91%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Puma Biotechnology Company Profile
Company profile explainedCompany Profile
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Key Executives
| Name | Position |
|---|---|
| Alan H. Auerbach | Founder, Chairman, President, Chief Executive Officer & Secretary |
| Maximo F. Nougues | Chief Financial Officer & Principal Accounting Officer |
| Douglas Hunt FRAPS | Chief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer |
| Gordon G. Esplin | Chief Accounting Officer |
| Heather Blaber | Senior Vice President of Marketing |
| Kenneth Wiehe | Senior Vice President of Supply Chain & Manufacturing |
| Mariann Ohanesian | Senior Director of Investor Relations |
| Pamela Wilson | Senior Vice President of Clinical Operations |
| Petra Rietschel | Senior Vice President of Clinical Development |
| Roger L. Storms | Senior Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 06, 2026 | SC 13D/A | [Amend] Filing |
| Sep 16, 2026 | 4 | Filing |
| Sep 16, 2026 | 4 | Filing |
| Aug 06, 2026 | 10-Q | Quarterly Report |
| Aug 06, 2026 | 8-K | Current Report |
| Jul 08, 2026 | 4 | Filing |
| Jul 08, 2026 | 4 | Filing |
| Jul 08, 2026 | 4 | Filing |
| Jun 16, 2026 | 8-K | Current Report |
| Jun 15, 2026 | 4 | Filing |
Puma Biotechnology
| Country | United States |
| IPO Date | Apr 24, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 179 |
| CEO | Alan H. Auerbach |
Contact Details
10880 Wilshire Boulevard Los Angeles,
California 90024 United States
Stock Details
| Ticker Symbol | PBYI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001401667 |
| CUSIP Number | 74587V107 |
| ISIN Number | US74587V1070 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove PBYI